Elyse Margolis

Elyse brings nearly 20 years of experience in integrated global healthcare communications. She has worked with a range of global healthcare clients including Pfizer, AstraZeneca, BMS, Novartis, GSK and Amgen at the brand, franchise and corporate levels helping them successfully communicate both externally and internally during times of significant change including franchise acquisitions and divestitures; corporate re-organizations; and leadership changes. She has also worked with her clients to develop distinct leadership SOV around complex issues including access, pricing and value.

Passionate about helping clients identify unique cross-sector collaborations to achieve specific, moment-in-time goals, Elyse has helped orchestrate partnerships that have successfully engaged policymakers and introduced innovative pilot programs and public/private partnerships that have driven new approaches to accelerate change.

Over the course of her career, Elyse has helped prepare the market for the launch of numerous first-of-kind therapies including the recent approval and launch of the first immunotherapy for acute lymphoblastic leukemia (ALL), blinatumomab, and the first oncolytic immunotherapy for metastatic melanoma, T-VEC. Others include the first fusion inhibitor for HIV, the first bone-building agent for osteoporosis and three novel mechanisms for major depressive disorder. Her teams have received numerous industry awards for breakout programming that have helped address complex awareness, stigma and public policy challenges.

Elyse graduated from the University of Wisconsin where she earned a Bachelor of Science degree in medical anthropology.